Patent application number | Description | Published |
20080274955 | Novel Use of a Polypeptide Comprising Fas-1 Domain - The present invention relates to the novel use of a polypeptide comprising a fas-1 domain. More particularly, the invention relates to a method for the inhibition of the adhesion, migration and/or proliferation of endothelial cells, and/or for the inhibition of angiogenesis, using the polypeptide comprising the fas-1 domain, or functional equivalents thereof. Furthermore, the invention provides a method for treating or preventing angiogenesis-related diseases, using the polypeptide. | 11-06-2008 |
20080280323 | Method for Producing Epidermal Growth Factor Using Fusion Proteins Comprising Fas-1 Domain - The present invention provides a fusion protein in which a polypeptide comprising Fas-1 domain is fused in frame to N-terminal or C-terminal of human EGF, a nucleotide sequence encoding the fusion protein, an expression vector containing the nucleotide sequence, a transformant transformed by the nucleotide sequence and a method for producing human EGF, improving stability of the protein and enhancing the functions of the same. The present invention provides human EGF with improved stability and enhanced functions by fusing a polypeptide comprising Fas-1 domain having the activities of cell adhesion and wound healing to human EGF. | 11-13-2008 |
20090028871 | NOVEL USE OF LIGANDS SPECIFIC TO FEX-2 POLYPEPTIDE - The present invention relates to novel use of a ligand specific to a FEX-2 polypeptide. More specifically, the present invention relates to methods for modulating the secretion of an inflammation-associated cytokine and for treating or preventing an inflammatory disease using the FEX-2-specific ligand. The ligand specific to the FEX-2 polypeptide can bind to FEX-2 expressed on the surface of phagocytes so that it can stimulate the secretion of anti-inflammatory cytokine and inhibit the secretion of inflammatory cytokine, so as to treat or prevent inflammatory diseases. | 01-29-2009 |
20090035314 | Method and pharmaceutical composition for preventing or treating diseases associated with inflammation - The present invention relates to a method and pharmaceutical composition for preventing or treating inflammatory diseases. More particularly, the present invention relates to a method for inhibiting lymphocyte adhesion to an endothelial cell, or a method for treating an inflammatory disease, which comprises administering to a subject in need thereof an inhibitor against lymphocyte adhesion to a FEX-2 polypeptide. A pharmaceutical composition comprising the inhibitor against lymphocyte adhesion to a FEX-2 polypeptide, and the use of the inhibitor against lymphocyte adhesion to a FEX-2 polypeptide are also disclosed. Further, a method for screening a medicament for inhibiting lymphocyte adhesion to a FEX-2 polypeptide or a medicament for treating an inflammatory disease, which comprises a step of selecting an inhibitor against lymphocyte adhesion to a FEX-2 polypeptide, is disclosed. | 02-05-2009 |
20090068189 | Monoclonal Antibody to Human TGF-Beta Induced Gene-H3 and Use Thereof - The present invention relates to a monoclonal antibody to human βig-h3 and the use thereof. More particularly, it relates to a monoclonal antibody to the human βig-h3 protein, wherein the epitope of the monoclonal antibody is the H1 region of the fourth fas-1 domain of the human βig-h3 protein. The monoclonal antibody can specifically recognize the human βig-h3 protein in tissue, and so will be useful in diagnosing a disease associated with the increase or decrease of the βig-h3 protein. In addition, the monoclonal antibody has the effect of inhibiting the cell adhesion activity of the βig-h3 protein. | 03-12-2009 |
20090074663 | Peptide for diagnosing, preventing and treating atherosclerosis and uses thereof - A peptide for diagnosing, preventing and treating atherosclerosis, and a use thereof, comprising an amino acid sequence as set forth in SEQ ID NO: 1 or SEQ ID NO: 2, and a use thereof. The peptide effectively targets atherosclerotic plaques, and binds to IL-4R to thereby exhibit antagonistic effects on IL-4-mediated signaling of cellular inflammatory reaction and survival reaction. The peptide of the present invention can be used for diagnosis of atherosclerosis, prevention and treatment of IL-4-induced inflammatory reaction and prevention and treatment of atherosclerosis which is primarily caused by the inflammatory reaction, as well as for prevention or treatment of atherosclerosis via conjugation with an anti-atherosclerotic drug. | 03-19-2009 |
20090214430 | POLYPEPTIDE SPECIFICALLY BOUND TO PHOSPHATIDYLSERINE AND THE USE THEREOF - The present invention relates to a polypeptide specifically bound to phosphatidylserine and use thereof, and more particularly to a polypeptide having an amino acid sequence designated as sequence number 1 and specifically bound to phosphatidylserine, a phosphatidylserine detecting composition containing the polypeptide as an active ingredient, a detecting method of phosphatidylserine by using polypeptide, a apoptotic cell detecting containing the polypeptide as an active ingredient, a drug delivery composition containing the polypeptide as an active ingredient, a composition for treatment and prevention of a tumorous disease, and a composition for visualization of a tumorous region. A polypeptide having an amino acid sequence designated sequence number 1 is specifically bound to phosphatidylserine. Therefore, the polypeptide of the present invention is useful for detecting phosphatidylserine, furthermore detecting apoptotic cells expressing phosphatidylserine on the surface of the cell and tumor cells, and also useful for visualization of apoptotic cells or tumor cells. | 08-27-2009 |
20090214435 | Recombinant vector expressing MDR1 shRNA and thymidine kinase and use thereof - A recombinant vector capable of expressing MDR1 shRNA and thymidine kinase, and a use thereof. More specifically, provided is a recombinant vector capable of efficiently expressing MDR1 shRNA and thymidine kinase in a host cell, a transfectant cell comprising the same recombinant vector, a composition for treating neoplastic diseases, comprising the same recombinant vector, and a method for imaging of neoplastic lesions using the same recombinant vector. The recombinant vector of the present invention is capable of achieving efficient intracellular expression of MDR1 shRNA and a thymidine kinase-GFP fusion protein within the host cell and is therefore highly effective for combined therapy of anticancer drugs. Further, the recombinant vector of the present invention enables imaging of neoplastic lesions. Therefore, the recombinant vector of the present invention can be used in combination with other anticancer drugs for treatment of neoplastic diseases. | 08-27-2009 |
20090285754 | PEPTIDES FOR TARGETING APOPTOTIC CELLS AND USES THEREOF - The present invention relates to a peptide capable of specifically targeting apoptotic cells undergoing apoptosis and a use thereof. More particularly, it relates to a peptide having an amino acid sequence represented by anyone selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 12 and targeting apoptotic cells, a composition for detection of apoptotic cells comprising the same as an effective ingredient, a composition for drug delivery comprising the same as an effective ingredient, a composition for imaging comprising the same as an effective ingredient and the like. The peptide of the present invention effectively detects apoptosis which is involved in tissues of neoplastic disease, myocardial infarction, stroke and arteriosclerosis. Accordingly, the peptide of the present invention may be used in imaging of diagnosis of the said diseases and reaction against a drug by binding imaging reagent and etc. as well as in protection and treatment for the said diseases by binding a treatment reagent and then delivering drug selectively. | 11-19-2009 |
20110150764 | STROKE-TAGETING PEPTIDE AND USE THEREOF - The present invention relates to stroke-targeting peptides and use thereof. More specifically, the present invention relates to a stroke-targeting peptide comprising an amino acid sequence selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 4 and use thereof. The peptide of the present invention can be specifically bound to stroke cells in the subject, and thus can be effectively used in diagnostic markers and kits for stroke, and compositions for drug delivery specific to stroke and pharmaceutical compositions and compositions for imaging stroke. | 06-23-2011 |
20120258038 | USES OF APOPTOTIC CELL-TARGETING PEPTIDES, LABEL SUBSTANCES AND LIPOSOMES CONTAINING A THERAPEUTIC AGENT FOR PREVENTING, TREATING OR THERAPEUTICALLY DIAGNOSING APOPTOSIS-RELATED DISEASES - The present invention relates to a composition for preventing, treating or theranosis of apoptosis-related diseases comprising liposome comprising apoptotic cell-targeting peptides, label substances and a therapeutic agent. The present invention may be used for drug delivery to the apoptotic cells in cancer or tumor mass, the apoptotic myocardial cells in myocardial infarction lesion, the apoptotic stroke cells in stroke lesion, the apoptotic cells in arteriosclerosis lesion and further may be used for detection of the cells and imaging diagnosis. Therefore, it can be used for theranosis as well as preventing or treating the diseases. | 10-11-2012 |
20120288447 | PEPTIDE WHICH PASSES THROUGH BLOOD-BRAIN BARRIER AND TARGETS APOPTOSIS OF NEURODEGENERATIVE BRAIN DISEASE SITE AND USES THEREOF - The present invention relates to a peptide that passes through a blood-brain barrier and targets apoptosis of neurodegenerative brain disease-affected sites and uses thereof. More particularly, the present invention relates to a composition for delivering drugs to brain tissues, a composition for detecting apoptotic cells of neurodegenerative brain disease-affected sites, and a composition for imaging the neurodegenerative brain disease-affected sites which comprises a peptide having an amino acid sequence represented by SEQ ID: No. 1 respectively, and a composition for prevention, treatment, or theranosis of neurodegenerative brain diseases comprising said peptide. The peptide of the present invention can be used for detecting apoptosis in neurodegenerative brain diseases and further detecting apoptotic cells (especially apoptotic neuronal cells) in neurodegenerative brain disease-affected sites and imaging, targeted drug delivery, theranosis. | 11-15-2012 |
20120294931 | TARGET-AIMING DRUG DELIVERY SYSTEM FOR DIAGNOSIS AND TREATMENT OF CANCER CONTAINING LIPOSOME LABELED WITH PEPTIDES WHICH SPECIFICALLY TARGETS INTERLEUKIN-4 RECEPTORS, AND MANUFACTURING METHOD THEREOF - The present invention relates to a target-aiming drug delivery system for diagnosis and treatment of cancer containing liposome labeled with peptides which specifically targets interleukin-4 receptors, and a manufacturing method thereof. The liposome which contains anticancer drugs labeled with IL4RPep peptides prepared in accordance with the present invention can deliver drugs to cancer cells in which IL-4 receptors are overexpressed by IL4RPep peptides which specifically bind to IL-4 receptors, and the drug delivery can recognize cancer cells specifically by a label. Thus, IL4RPep peptides can increase the effect of drugs only on cancer tissues and at the same time significantly reduce the side effects on normal tissues, which makes possible in vivo(molecular) imaging and early diagnosis of tumors. Therefore, the liposome which contains anticancer drugs labeled with IL4Pep peptides of the present invention can be applied, as the target-aiming drug delivery system, effectively to the diagnosis and treatment of cancers. | 11-22-2012 |
20120316101 | PEPTIDES FOR TARGETING APOPTOTIC CELLS AND USES THEREOF - The present invention relates to a polypeptide capable of specifically targeting apoptotic cells undergoing apoptosis and a use thereof. More particularly, it relates to an isolated polypeptide consisting of the sequence (I): Cys-X1-Val-Ala-Pro-X2 (I), wherein X1 is an amino acid with polar uncharged side chain and X2 is an amino acid with positive charged side chain and targeting apoptotic cells, a composition for detection of apoptotic cells comprising the same as an effective ingredient, a composition for drug delivery comprising the same as an effective ingredient, a composition for imaging comprising the same as an effective ingredient and the like. Accordingly, the peptide of the present invention may be useful for detection of apoptotic cells, as well as detection and imaging of apoptotic cells in tumor tissue, apoptotic myocardial cells in myocardial infarction tissue, apoptotic nerve cells in stroke tissue and arteriosclerosis site, and targeted drug delivery thereto. | 12-13-2012 |
20140079643 | PROTEIN SKELETAL MODULE WHICH INCREASES THE BINDING AFFINITY AND BINDING SPECIFICITY OF ACTIVE POLYPEPTIDES - The present invention relates to a novel protein skeletal module which increases the binding affinity or binding specificity of active polypeptides. More particularly, the present invention relates to a protein skeletal module comprising polypeptides consisting of the 1 | 03-20-2014 |
20140147453 | FUSION PEPTIDE COMPRISING dhFas-1 DOMAIN AND MMP SUBSTRATE AND USE THEREOF FOR PREVENTING AND TREATING RHEUMATOID ARTHRITIS - The present invention relates to a fusion peptide comprising dhFas-1 domain and MMP substrate and use thereof. More specifically, the present invention relates to a fusion peptide, comprising a) a dhFas-1 domain which is the fourth fas-1 domain of βig-h3 lacking H1 and H2 regions; b) a MMP (Matrix metalloproteinase) substrate; and c) a peptide comprising RGD motif and an use thereof for preventing and treating inflammatory disease. The fusion peptide of the present invention inhibits expension of rheumatoid arthritis by adhesion and migration of sinoviocytes and may be used for preventing or treating inflammatory disease by inhibiting infiltration of immune cells. | 05-29-2014 |
20140288300 | DRUG-FLUOROPHORE COMPLEX FOR SPECIFIC DETECTION OF TUMOR CELLS - Disclosed is a drug-fluorophore complex for specific detection of tumor cells. Specifically, the drug-fluorophore complex includes a tumor cell-targeting drug penetrating tumor cells and non-tumor cells at different rates or levels, and a fluorescent substance chemically bonded to the tumor cell-targeting drug. The drug-fluorophore complex enables specific imaging of tumor cells only with high accuracy in a very simple manner without causing cytotoxicity. | 09-25-2014 |
20150051269 | Drug Delivery Conjugate Capable of Controlled Release, and Use Thereof - The present invention relates to a hydrophobic drug delivery conjugate, to which cyclodextrin, poly(maleic anhydride), and a hydrophobic drug are bonded, and to a pharmaceutical composition comprising the hydrophobic drug delivery conjugate as an active ingredient. The hydrophobic drug delivery conjugate according to the present invention can effectively control the release rate and the delivery rate of a hydrophobic drug by regulating the physicochemical bonding and/or composition of the cyclodextrin, poly(maleic anhydride), and hydrophobic drug, and can also increase the effect of the drug by significantly increasing the solubility of the hydrophobic drug. Further, the present invention can enable the type of the hydrophobic drug to be varied, as well as a peptide having target directivity to be introduced into a surface of the conjugate, such that the present invention can be applied to the treatment of various diseases in addition to cancer treatment. | 02-19-2015 |